The GoodRx Prescription Savings Blog

The latest updates on prescription drugs and ways to save from the GoodRx medical team

Adlyxin for Diabetes Type 2 Now Available in Pharmacies

by The GoodRx Pharmacist on May 31, 2017 at 3:23 pm

Back in July, the FDA approved Adlyxin for diabetes type 2, and it is now available in pharmacies!

When people think about injectable diabetes medications, the first thing that comes to mind tends to be insulin medications like Humalog (insulin lispro) or Lantus (insulin glargine). However, the FDA has been approving many new non-insulin products recently, like Victoza and Byetta, and now Adlyxin!

What isĀ Adlyxin indicated for?

Adlyxin is a GLP-1 agonist, a hormone that helps stimulate the production of insulin and normalize blood sugar levels. It is indicated for the treatment of adult patients with type 2 diabetes, in conjunction with diet and exercise.

Adlyxin is currently available in over 60 countries under the name of Lyxumia and has been approved in Europe since 2013.

How is Adlyxin to be used?

Adlyxin is available in a disposable pre-filled pen in strengths of 50 mcg/ml and 100 mcg/ml. Adlyxin is to be injected subcutaneously, once daily, an hour before the first meal of the day. For the first 14 days of treatment, patients will use the 10 mcg pen. On day 15, the dosage should be increased to 20 mcg once daily.

What are the common side effects associated with Adlyxin?

Possible side effects include nausea, vomiting, headache, diarrhea, dizziness, and low blood sugar. Be sure to speak with your doctor if you experience any of these side effects for a prolonged period of time.

How does Adlyxin compare to other medications in its class?
Adlyxin is similar to medications like Victoza and Byetta, as they all require once-daily injections. However, other medications, like Bydureon, Trulicity, and Tanzeum are once-weekly injections. There are pros and cons to both of these types, so be sure to speak with your doctor to discuss which will be best for you.

For more information, see the press announcement from the FDA here. You can also read Sanofi’s press announcement here.


Copyright ©2015 GoodRx, Inc.

This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment. Third party logos, trademarks, brand names and images contained on GoodRx.com are for demonstration purposes only and are owned by their respective rights holders, who are not affiliated with this Site.